Dissecting Spesolimab's Approval With Boehringer Ingelheim's Carine Boustany
Business Of Biotech
00:00
The Challenges in BI
There were a lot of challenges in finding the right molecules, and convincing others that we should position the molecules for GPP. Wehringer Ingleheim is very patient-centric; this was the epitome of patient-centricity. It's probably one of the biggest proof you can ever have in science that it's relevant for this disease.
Transcript
Play full episode
